Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Arbor Biotechnologies has raised $73.9M in total funding. The most recent round was Series C. The last funding was announced in March 2025.
Arbor Biotechnologies's investors include Temasek, ARCH Venture Partners, Janus Henderson Investors, GreatPoint Ventures, TCG Crossover.
Arbor Biotechnologies is headquartered in Cambridge, United States.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Arbor Biotechnologies is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arbor Biotechnologies — Funding & Investors." VCBacked, March 18, 2025, https://www.vcbacked.co/company/arbor-biotechnologies. Accessed October 31, 2026.
VCBacked. (2025). Arbor Biotechnologies — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/arbor-biotechnologies
{{cite web |title=Arbor Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/arbor-biotechnologies |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated